Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ALK pERKs up MYCN in neuroblastoma.

Science signaling - 28 Oct 2014

Lindner Sven, Henssen Anton, Astrahantseff Kathy, Schulte Johannes H

Abstract excerpt

The gene expressing the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) is mutated and aberrantly expressed in several cancers. The clinical efficacy of the ALK inhibitor, crizotinib, lags behind expectations for treating MYCN-amplified, ALK-mutant neuroblastoma, a deadly childhood cancer. In this issue of Science Signaling, Umapathy et al. identify the kinase extracellular signal-regulated kinase 5...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Gene Expression Regulation, Neoplastic
Share to N-Myc Proto-Oncogene Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neuroblastoma

Share to Nuclear Proteins

Share to Oncogene Proteins

Share to Receptor Protein-Tyrosine Kinases

Share to Signal Transduction

Source

Identifiers

PMID: 25351246
DOI: 10.1126/scisignal.2005940

Genes

ALK
MYCN
MYC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ALK pERKs up MYCN in neuroblastoma.PMID 25351246Read ↗

The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastomaSemantic proximity Read ↗

ALK in Neuroblastoma: Biological and Therapeutic ImplicationsSemantic proximity Read ↗

New strategies in neuroblastoma: Therapeutic targeting of MYCN and ALK.Semantic proximity Read ↗

Cell Survival Signaling in NeuroblastomaSemantic proximity Read ↗

The ETS transcription factor ETV5 is a target of activated ALK in neuroblastoma contributing to increased tumour aggressivenessSemantic proximity Read ↗

Phosphoproteomics reveals ALK promote cell progress via RAS/JNK pathway in neuroblastomaSemantic proximity Read ↗

Neuroblastoma and MYCN.Semantic proximity Read ↗

ALK Inhibitors in Neuroblastoma: A Sprint from Bench to Bedside.Semantic proximity Read ↗

Targeting anaplastic lymphoma kinase in neuroblastomaSemantic proximity Read ↗

Transcription factor activating protein 4 is synthetically lethal and a master regulator of MYCN-amplified neuroblastomaSemantic proximity Read ↗

The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma.Semantic proximity Read ↗

A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.